Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.70 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | XDH | P47989 | 2/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599162 | 0.90 | KDM4E (0.77) | FLT3SRD5A2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3057182 | 0.88 | FLT3 (0.64) | FLT3SRD5A2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL3030893 | 0.87 | SRD5A2 (0.80) | FLT3SRD5A2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL30920873 | 0.87 | SRD5A2 (0.80) | FLT3SRD5A2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL6087004 | 0.85 | FLT3 (0.66) | FLT3SRD5A2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL20535417 | 0.82 | XDH (0.80) | FLT3KDM4EALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL23168304 | 0.81 | XDH (0.52) | FLT3SRD5A2KDM4EALDH1A1HPGD | |
| SCHEMBL3886236 | 0.81 | XDH (0.56) | FLT3KDM4EALDH1A1HPGDPDGFRB | |
| SCHEMBL7159304 | 0.81 | SRD5A2 (0.82) | FLT3SRD5A2KDM4EALDH1A1CYP1A2 | |
| SCHEMBL7168633 | 0.81 | SRD5A2 (0.56) | FLT3SRD5A2KDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11547762-B2 | Methods for preparing antibody drug conjugates | GENENTECH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3522933-B1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | HOFFMANN LA ROCHE (CH) | 2021-12-15 | — | — | EP | disclosed |
| US-20190201544-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | GENENTECH, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018065501-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-04-12 | — | — | WO | disclosed |
| US-5866589-A | Alkyl substituted piperadinyl and piperazinyl anti-AIDS compounds | PHARMACIA & UPJOHN COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0797576-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018628-A1 | ALKYL SUBSTITUTED PIPERADINYL AND PIPERAZINYL ANTI-AIDS COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233700-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | FLT3 2248/4885SRD5A2 3933/4885KDM4E 1929/4885 |
| US-11547762-B2 | Methods for preparing antibody drug conjugates | FCGRT, MSN, FCGR3B | FLT3 2248/4885SRD5A2 3933/4885KDM4E 1929/4885 |
| US-20190201544-A1 | METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES | FCGRT, MSN, FCGR3B | FLT3 2248/4885SRD5A2 3933/4885KDM4E 1929/4885 |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | FLT3 3961/4885SRD5A2 975/4885KDM4E 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.